At the heart of the Oncopole
At the heart of the Oncopole of Toulouse, the CRCT, together with all its partners (institutional, academic, clinical, industrial, charities…), stimulates innovation in terms of research and teaching in the fight against cancer.
The CRCT leads an integrated approach between research, care and teaching, in a transversal and multidisciplinary logic.
The CRCT is a joint Research Unit Inserm & University Toulouse III Paul Sabatier
3 research teams are also labelled by the CNRS
Researchers, clinicians and supports
PhD students and post-doctoral fellows
Discover in this France 3 TV report the collaboration between the CRCT team led by Dr. Pierre Cordelier and the Toulouse start-up Neovirtech: a therapeutic innovation opening up new perspectives in the treatment of cancer. [video width="960" height="540"...read more
Focus: IMMUSPHINX program – Targeting sphingolipid metabolism to improve the efficacy of immunotherapies in melanoma
Thanks to anticancer immunotherapies targeting immune checkpoints, the proportion of patients with metastatic melanoma (MM) in remission after 5 years has tripled during the last years. However, therapeutic options are sparse for patients who do not respond to...read more
Melanoma is a poor-prognosis skin cancer. Immunotherapy based on the use of monoclonal antibodies (anti-CTLA-4 and anti-PD-1) activates the immune system to fight melanoma and has improved the prognosis of this cancer. Those antibodies block checkpoints, which act as...read more
- Friday 29 June - 13:00 à 14:30 at Auditorium Claudius Regaud
Dr. Vanesa GOTTIFREDI / Oncogenic and antioncogenic signals triggered by the impairment of pol-eta mediated DNA damage toleranceMonday 25 June - 11:00 à 12:30 at Salle C. Cazaux
Centre de Recherches en Cancérologie de Toulouse
2 avenue Hubert Curien
31037 TOULOUSE CEDEX 1 – FRANCE